Contraindicated in:
Use Cautiously in:
Derm: pruritus, rash.
Endo: THYROID C-CELL TUMORS.
GI: abdominal pain, nausea, vomiting, ↓ appetite, cholecystitis, cholelithiasis, constipation, diarrhea, dyspepsia, PANCREATITIS.
GU: acute renal failure.
Local: injection site reactions.
Neuro: fatigue.
Misc: HYPERSENSITIVITY REACTIONS (INCLUDING ANAPHYLAXIS AND ANGIOEDEMA).
Drug-Drug:
Type 2 Diabetes
Risk Reduction of Major Cardiovascular Events
Absorption: 0.75 mg dose: 65% absorbed following SUBQ administration; 1.5 mg dose: 47% absorbed following SUBQ administration.
Distribution: Unknown.
Metabolism/Excretion: Degraded by protein catabolic processes.
Half-life: 5 days.
NDC Code*